These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
527 related articles for article (PubMed ID: 10440399)
1. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399 [TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Sollinger HW Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033 [TBL] [Abstract][Full Text] [Related]
3. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657 [TBL] [Abstract][Full Text] [Related]
4. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182 [TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266 [TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752 [TBL] [Abstract][Full Text] [Related]
8. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503 [TBL] [Abstract][Full Text] [Related]
9. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102 [TBL] [Abstract][Full Text] [Related]
10. [Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. Kuriata-Kordek M; Boratyńska M; Urbaniak J; Woźniak M; Patrzałek D; Szyber P; Klinger M Pol Merkur Lekarski; 2006 Aug; 21(122):161-3; discussion 164. PubMed ID: 17144102 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194 [TBL] [Abstract][Full Text] [Related]
12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181 [TBL] [Abstract][Full Text] [Related]
14. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117 [TBL] [Abstract][Full Text] [Related]
15. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Gourishankar S; Houde I; Keown PA; Landsberg D; Cardella CJ; Barama AA; Dandavino R; Shoker A; Pirc L; Wrobel MM; Kiberd BA Clin J Am Soc Nephrol; 2010 Jul; 5(7):1282-9. PubMed ID: 20498245 [TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate Mofetil Acute Renal Rejection Study Group Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415 [TBL] [Abstract][Full Text] [Related]
19. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Moreso F; Serón D; Morales JM; Cruzado JM; Gil-Vernet S; Pérez JL; Fulladosa X; Andrés A; Grinyó JM Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510 [TBL] [Abstract][Full Text] [Related]
20. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Kim YS; Moon JI; Kim SI; Park K Transplantation; 1999 Aug; 68(4):578-81. PubMed ID: 10480420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]